Across TCGA pan-cancer cohorts, NAP1L6P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NAP1L6P data layer compared with 18 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher NAP1L6P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAP1L6P expression acts as an unfavorable survival marker.

SARC are the cancer types where NAP1L6P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.081	0.632	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: NAP1L6P tumor-vs-normal RNA expression · all NAP1L6P data types